Spatial analysis of advanced-stage ovarian cancer mortality in California

被引:27
作者
Bristow, Robert E. [1 ,2 ]
Chang, Jenny [3 ]
Ziogas, Argyrios [3 ]
Gillen, Daniel L. [2 ,4 ]
Bai, Lu [4 ]
Vieira, Veronica M. [4 ,5 ]
机构
[1] Univ Calif Irvine, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Orange, CA 92717 USA
[2] Univ Calif Irvine, Med Ctr, Ctr Comprehens Canc, Orange, CA 92717 USA
[3] Univ Calif Irvine, Sch Med, Dept Epidemiol, Irvine, CA 92717 USA
[4] Univ Calif Irvine, Sch Med, Dept Stat, Irvine, CA 92717 USA
[5] Univ Calif Irvine, Sch Med, Program Publ Hlth, Irvine, CA 92717 USA
基金
美国国家卫生研究院;
关键词
geographic location; ovarian cancer; TREATMENT GUIDELINES; REGIONAL-VARIATION; CARE; WOMEN; DISPARITIES; SURVIVAL; SURGERY; TRENDS; IMPACT; CHEMOTHERAPY;
D O I
10.1016/j.ajog.2015.01.045
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: We sought to determine the impact of geographic location on advanced-stage ovarian cancer mortality in relation to adherence to National Comprehensive Cancer Network (NCCN) treatment guidelines and hospital case volume. STUDY DESIGN: This was a retrospective observational cohort study of patients diagnosed with stage IIIC/IV epithelial ovarian cancer (Jan. 1, 1996, through Dec. 31, 2006) identified from the California Cancer Registry. Generalized additive models were created to assess the effect of spatial distributions of geographic location, demographic characteristics, disease-related variables, adherence to NCCN guidelines, and hospital case volume, with simultaneous smoothing of geographic location and adjustment for confounding variables. RESULTS: A total of 11,765 patients were identified. Twelve of the 378 hospitals (3.2%) were high-volume hospitals (HVH) (>= 20 cases/y) and cared for 2112 patients (17.9%). For all patients, the median distance to an HVH was 22.7 km/14.1 miles and 80% were located within 79.6 km/49.5 miles of an HVH. Overall, 45.4% of patients were treated according to NCCN guidelines. The global test for location revealed that geographic position within the state was significantly correlated with ovarian cancer mortality after adjusting for other variables (P < .001). Distance to receive care >= 32 km/20 miles was protective against mortality (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.79-0.93), while distance from an HVH >= 80 km/50 miles was associated with an increased risk of death (HR, 1.13; 95% CI, 1.03-1.23). The effects of geographic predictors were attenuated when nonadherence to NCCN guidelines (HR, 1.25; 95% CI, 1.18-1.32) and care at an HVH (HR, 0.87; 95% CI, 0.81-0.93) were introduced into the model. CONCLUSION: Geographic location is a significant predictor of advanced-stage ovarian cancer mortality and the effect is primarily related to the likelihood of receiving NCCN guideline adherent care and treatment at an HVH.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Increasing Rates of No Treatment in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Propensity-Matched Analysis
    David, Elizabeth A.
    Daly, Megan E.
    Li, Chin-Shang
    Chiu, Chi-Lu
    Cooke, David T.
    Brown, Lisa M.
    Melnikow, Joy
    Kelly, Karen
    Canter, Robert J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (03) : 437 - 445
  • [22] Neoadjuvant chemotherapy in advanced-stage ovarian cancer - state of the art
    Margioula-Siarkou, Chrysoula
    Petousis, Stamatios
    Papanikolaou, Alexios
    Gullo, Giuseppe
    Margioula-Siarkou, Georgia
    Lagana, Antonio Simone
    Dinas, Konstantinos
    Guyon, Frederic
    MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY, 2022, 21 (04): : 272 - 275
  • [23] Clinical experience in chemotherapy treatment for advanced-stage ovarian cancer
    Dumitru, M.
    Fagarasanu, Monica
    Cezar, Cristina
    Badescu, S.
    Tudosa, Rodica
    Soloviev, D.
    Vartej, P.
    GINECO RO, 2009, 5 (04): : 252 - 256
  • [24] Role of obesity in the surgical management of advanced-stage ovarian cancer
    Wolfberg, AJ
    Montz, FJ
    Bristow, RE
    JOURNAL OF REPRODUCTIVE MEDICINE, 2004, 49 (06) : 473 - 476
  • [25] Rectosigmoidian Involvement in Advanced-stage Ovarian Cancer - Intraoperative Decisions
    Bacalbasa, Nicolae
    Balescu, Irina
    Dima, Simona
    IN VIVO, 2017, 31 (05): : 973 - 977
  • [26] Treatment and outcome of elderly patients with advanced stage ovarian cancer: A nationwide analysis
    Schuurman, M. S.
    Kruitwagen, R. F. P. M.
    Portielje, J. E. A.
    Roes, E. M.
    Lemmens, V. E. P. P.
    van der Aa, M. A.
    GYNECOLOGIC ONCOLOGY, 2018, 149 (02) : 270 - 274
  • [27] Does Neoadjuvant Chemotherapy Impact Prognosis in Advanced-Stage Epithelial Ovarian Cancer Optimally Debulked at Surgery?
    Al Mutairi, Nashmia
    Le, Tien
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2019, 41 (02) : 185 - 190
  • [28] Centralization of care for patients with advanced-stage ovarian cancer - A cost-effectiveness analysis
    Bristow, Robert E.
    Santillan, Antonio
    Diaz-Montes, Teresa R.
    Gardner, Ginger I.
    Giuntoli, Robert L., II
    Meisner, Benjamin C.
    Frick, Kevin D.
    Armstrong, Deborah K.
    CANCER, 2007, 109 (08) : 1513 - 1522
  • [29] Predicting 6-and 12-Month Risk of Mortality in Patients With Platinum-Resistant Advanced-Stage Ovarian Cancer Prognostic Model to Guide Palliative Care Referral
    Foote, Jonathan
    Lopez-Acevedo, Micael
    Samsa, Gregory
    Lee, Paula S.
    Kamal, Arif H.
    Secord, Angeles Alvarez
    Havrilesky, Laura J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (02) : 302 - 307
  • [30] Association of malignant ascites with systemic inflammation and muscle loss after treatment in advanced-stage ovarian cancer
    Weng, Chia-Sui
    Huang, Wan-Chun
    Chang, Chih-Long
    Jan, Ya-Ting
    Chen, Tze-Chien
    Lee, Jie
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2023, : 2114 - 2125